Open the era of digital medicine for brain health
SDODT founded in 2021, is an innovative digital therapeutics technology company focusing on independent research and development, and is a member of the Century Huatong Group.
Based on cutting-edge neuroscientific researches, biosensor technologies and AI analysis, SDODT is dedicated to providing digital solutions for the diagnosis and treatment of brain and mental diseases, as well as promoting the development of precise digital therapeutics in multiple fields and the frontier research of brain neuroscience.
SDODT has always adhered to the spirit of active innovation and forge ahead, taking clinical needs as the core, relying on EEG bioinformatics technology and core algorithm analysis, to develop technologies, products and platforms suitable for digital therapy, and create efficient, convenient and universal digital therapy.
SDODT has gathered a group of excellent, multidisciplinary and interdisciplinary experts, and has cooperated with TCCI to develop the VR system for elderly rehabilitation, independently developed the Attention Enhancement Training Software System for Children ADHD, the VR Assessment and Intervention System for Autism, and the sleep monitoring system - Digital Sleep, which has laid a solid foundation for the wider application of digital medical technology.
In the future, SDODT will continue to strengthen the innovative R&D to explore and understand the human brain, help people improve their mental health, serve the society, and provide health protection for a better life for mankind.
Mission - Open the digital medicine era for brain health
Vision - better provide people with psychotherapy
SDODT successfully joined the brain-computer interface industry alliance and became a member unit
SDODT successfully settled in the post-doctoral innovation practice base in Pudong New Area
SDODT and Sea Tiger Health jointly build the "Sea Tiger Health Digital Sleep Center" to create a full-process sleep health medical management service
SDODT won the Top 10 Excellent Enterprise in Digital Therapy in China
SDODT participated in the World Summit of Medical Science and Technology, and its "Attention Enhancement Training Software" won the top 100 award for the best digital and information products/solutions in 2022
the digital medicine intelligent autism VR evaluation and intervention project participated in the 2022 World VR Industry Conference
the new product launch of Sleep Monitoring System was successfully held, and the product officially entered the market
SDODT started a new clinical trial in Zhejiang University Children's Hospital for the ADHD product
SDODT moved to a new residence and began a new chapter in the development of digital medicine
SDODT signed a contract for the key project of artificial intelligence of Shanghai Pudong Zhangjiang Group
ADHD products have obtained clinical trial results, and digital therapy products developed for ADHD have been proved effective in clinical trials
the "digital sleep" product of SDODT was promoted to participate in SAIL Award of 2022 World AI Conference (Outstanding AI Leader Award)
SDODT joined the Shanghai Artificial Intelligence Industry Association and AI Medical Special Committee
Officially renamed Shanghai Digital Medicine Intelligent Technology Co., Ltd
SDODT successfully assisted the first artificial intelligence and digital medical innovation forum of Central South Xiangya Hospital;
SDODT started a clinical trial in the Pediatric Hospital affiliated to Fudan University (the National Children's Medical Center) for the ADHD product
SDODT and VBData jointly held FOCUS 2022 digital therapy online salon - innovative exploration of digital therapy empowering the diagnosis and treatment of brain-related diseases
SDODT joined the China Rehabilitation Technology Transformation and Development Promotion Association, and became one of the main members of the China Rehabilitation Technology Transformation and Development Promotion Association
SDODT was established
cooperate with TCCI to develop VR products for elderly rehabilitation
Shengqu Games and Zhejiang University jointly established the "Legend Innovation Center" to promote the development of digital medicine industry
the R&D team was incubated in Shanghai Shengqu Games (formerly Shanda Games Ltd.) Research Institute
joined the China Digital Therapy Alliance and became one of the main members of the China Digital Therapy Alliance
A team of 50 experts
Aiming to provide the solution of
Autism | ADHD | Sleep Disorders | etc.
From sleep research, neuroscience, behavioral therapy, mechanical engineering, machine learning, electronic design, embedded system, testing, ergonomics, application and software development, product design and so on,
We are united by a common goal: to break through the boundaries of neuroscience and bring effective treatment and improvement to patients with brain and neurological diseases around the world.
Winner of Zhejiang Outstanding Youth Fund, "151" talent of Zhejiang Province. From December 2006 to January 2009, the visiting associate professor of Stanford University in the United States (the first batch of recipients of the "New Star Program" of Zhejiang University). From June 2010 to January 2011, he was a senior visiting scholar at the University of Indiana. Member of the Standing Committee of the Special Committee on New Biomarkers of the Zhejiang Society of Mathematical and Physical Medicine, and member of the Pediatric Neurology Group of the Pediatric Branch of the Zhejiang Medical Association. He was also the deputy director of the Brain Science Committee of the Pediatric Branch of Chinese Medical Association and the director of the Zhejiang Neuroscience Association. Presided over dozens of provincial and ministerial-level scientific research projects, including the general projects of the National Natural Science Foundation (4), the sub-projects of the National Key Research and Development Plan (1), the outstanding youth team of the Zhejiang Natural Science Foundation (1), and the "Qianjiang Talents" of the Zhejiang Provincial Department of Science and Technology (1). Published more than 50 academic papers, and SCI included more than 40. The team mainly carried out a series of research on the pathogenesis and prevention strategies of epilepsy, brain developmental disorders and cerebral ischemia injury. Experimental techniques include brain slices and in vivo patch clamp, high-resolution calcium imaging of zebrafish whole brain, gene manipulation, molecular biology, etc. The role of ATP-sensitive potassium channel, astrocyte conductance, GABA conductance and excitatory autosynapse in the pathogenesis of brain developmental disorders has been deeply discussed and some breakthroughs have been made.
专攻“视觉神经可塑性与信息编码机制”，精通视觉神经科学、神经电生理学、双光子在体成像、脑机接口相关学科。目前关注睡眠脑电算法、精神疾病的神经机制等前沿领域。
研究方向为“视觉功能及神经生物学新技术”，精通在体电生理、光遗传调控、虚拟现实、双光子成像等技术在视觉研究中的应用。目前主要关注脑机接口、虚拟现实等前沿技术在医疗领域尤其是自闭症谱系儿童干预中的应用。
研究领域为神经编码方向，专攻“记忆的形成过程和编码机制”。精通大脑的学习记忆功能、神经电生理学、脑机接口等。目前关注人工智能医疗、脑机接口应用、大脑编码信息的基本模式，睡眠的电生理特征、各类神经退行性疾病和精神疾病的发病机制和诊疗方法等前沿领域。
Winner of Zhejiang Outstanding Youth Fund, "151" talent of Zhejiang Province. From December 2006 to January 2009, the visiting associate professor of Stanford University in the United States (the first batch of recipients of the "New Star Program" of Zhejiang University). From June 2010 to January 2011, he was a senior visiting scholar at the University of Indiana. Member of the Standing Committee of the Special Committee on New Biomarkers of the Zhejiang Society of Mathematical and Physical Medicine, and member of the Pediatric Neurology Group of the Pediatric Branch of the Zhejiang Medical Association. He was also the deputy director of the Brain Science Committee of the Pediatric Branch of Chinese Medical Association and the director of the Zhejiang Neuroscience Association. Presided over dozens of provincial and ministerial-level scientific research projects, including the general projects of the National Natural Science Foundation (4), the sub-projects of the National Key Research and Development Plan (1), the outstanding youth team of the Zhejiang Natural Science Foundation (1), and the "Qianjiang Talents" of the Zhejiang Provincial Department of Science and Technology (1). Published more than 50 academic papers, and SCI included more than 40. The team mainly carried out a series of research on the pathogenesis and prevention strategies of epilepsy, brain developmental disorders and cerebral ischemia injury. Experimental techniques include brain slices and in vivo patch clamp, high-resolution calcium imaging of zebrafish whole brain, gene manipulation, molecular biology, etc. The role of ATP-sensitive potassium channel, astrocyte conductance, GABA conductance and excitatory autosynapse in the pathogenesis of brain developmental disorders has been deeply discussed and some breakthroughs have been made.
专攻“视觉神经可塑性与信息编码机制”，精通视觉神经科学、神经电生理学、双光子在体成像、脑机接口相关学科。目前关注睡眠脑电算法、精神疾病的神经机制等前沿领域。
研究方向为“视觉功能及神经生物学新技术”，精通在体电生理、光遗传调控、虚拟现实、双光子成像等技术在视觉研究中的应用。目前主要关注脑机接口、虚拟现实等前沿技术在医疗领域尤其是自闭症谱系儿童干预中的应用。
研究领域为神经编码方向，专攻“记忆的形成过程和编码机制”。精通大脑的学习记忆功能、神经电生理学、脑机接口等。目前关注人工智能医疗、脑机接口应用、大脑编码信息的基本模式，睡眠的电生理特征、各类神经退行性疾病和精神疾病的发病机制和诊疗方法等前沿领域。
Relevant policies and trends of digital therapy industry
2022年10月10日，海南省发布《海南省加快推进数字疗法产业发展的若干措施》，21条措施直击当前数字疗法产业发展痛点，特别是在科研、临床、推广、支付等方面给出了明确支持与鼓励，使其成为国内乃至全球首次推出的全周期数字疗法产业支持政策。
In January 2022, Hainan Province issued the "Fourteenth Five-Year Plan" for the Development of Digital Health in Hainan Province, which is the first time that "digital therapy" has been included in the provincial plan. In October 2022, Hainan Province issued "Several Measures to Accelerate the Development of Digital Therapy Industry in Hainan Province", which is the first special policy document supporting the development of digital therapy industry at the provincial level in China. These two documents have aroused strong concern in the industry, provided strong guidance for the development of digital therapy industry in Hainan Province, and also injected strong impetus into the progress of digital therapy in China.
2021年12月，国内首家数字疗法产业园区--杭州市数字疗法产业园区在杭州市高新区(滨江)政府的指导和支持下成立。
2021年7月23日，杭州市发布《关于加快生物医药产业高质量发展若干意见》中提到“加强医保体系对创新产业应用支撑”“推进数字健康融合发展”“支持本地医疗机构参与数字疗法产业购买服务试点”等政策。该文件也是全国首个明确支持和发展数字疗法的重要政策文件。
2020年11月，中国国家药品监督管理局（National Medical Products Administration，NMPA）批准了首个数字疗法Ⅱ类医疗器械，揭开了中国数字疗法的序幕。
2020年5月，德国联邦药品和医疗器械管理局(BfArM) 为DiGA(德国数字疗法) 正式实施快速审批程序，其中15款数字疗法产品获正式审批。
2020年4月，中国首个数字疗法正式组织——中国康复技术转化及发展促进会数字疗法系统工程专业委员会(CDTSP(pre))成立。
2020年4月，美国卫生与公众服务部以及FDA联合发布了《用于在新冠疫情期间治疗心理疾病的数字健康设备的强制政策》。
2017年，全球首个数字疗法联盟——Digital Therapeutics Alliance (数字疗法联盟)成立；截止目前，全球认证会员企业已超过100个。
2017年7月，FDA 下属的医疗器械和放射健康中心 (CDRH，Center for Devicesand Radiological Health) 发布了数字健康创新行动计划 (Digital Health InnovationAction Plan)，是数字健康产品发展的奠基性政策文件。
10F, Building 2, 58 Haiqu Road, Pudong District, Shanghai, China
Email：market@sdodt.com
